18.204.214.205
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Retina

Algorithm Appears to Aid Diabetic Retinopathy Accuracy

Posted on

Ophthalmologists can increase the confidence in the accuracy of their diabetic retinopathy diagnoses by using deep learning algorithms, according to a recent evaluation involving nearly 1,800 retinal fundus images.

Five general ophthalmologists, four retina specialists and one retina fellow read each image under one of the following circumstances: unassisted, grades only (a histogram of diabetic retinopathy predictions from a deep-learning model), and grades plus explanatory heatmaps. Among the results: 

  • Clinicians made more accurate diagnoses in the grades-only scenario, vs unassisted.
  • Adding the heatmap improved diabetic retinopathy diagnostic accuracy, but lessened it for non-diabetic retinopathy diagnoses.
  • Reader sensitivity increased with both types of assistance. For moderate non-proliferative diabetic retinopathy or worse, unassisted showed 79% accuracy, vs 88% for grades only and 89% when the heatmap was added; specificity remained high across all three scenarios. 
  • Retina specialists experienced greater accuracy with model assistance than unassisted readers or just the model.
  • Clinician confidence in their diagnosis and duration of task increased with model assistance.
  • Grades + heatmap and grades only were equally effective in most cases.
  • Duration of task lessened over time for all conditions, but made the biggest drop for grades + heatmap.

Sayres R, Taly A, Rahimy E, et al. Using a deep learning algorithm and integrated gradients explanation to assist grading for diabetic retinopathy. [Published online ahead of print December 13, 2018]. Ophthalmology. 2018;44(5):557-565. doi: https://doi.org/10.1016/j.ophtha.2018.11.016.

-Advertisement-
Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-